In a swarm of lawsuits, the company stood accused of selling a potentially cancer-causing medication. Thanks largely to news of a crucial legal settlement, GSK (GSK 5.84%) was one of the better-performing big pharma stocks on Wednesday. Relieved investors showed their appreciation by collectively bidding the company's shares up by 5.8% on the day, a performance that easily eclipsed the 0.7% rise of the benchmark S&P 500 index. $2.2 billion-plus in settlements That news concerns a discontinued version of GSK ...

文章核心观点 - 英国制药公司GSK同意支付最高22亿美元(约17亿英镑)来解决在美国针对其胃药Zantac的诉讼 [1] - GSK表示已与10家原告律师事务所达成协议,这些律师事务所代表了约93%,即约8万起美国州法院产品责任案件 [1] - 原告声称Zantac(泮托拉唑)导致他们患癌,但GSK表示没有证据表明Zantac会增加患癌风险,并且在和解中没有承认任何责任 [1] - GSK还同意支付7000万美元,解决Valisure(一家独立实验室)提出的Zantac投诉,该实验室在2019年发现Zantac可能产生致癌物质 [2] 公司相关 - GSK表示这些和解有利于公司和股东的长远利益,因为可以消除与持续诉讼相关的重大财务不确定性、风险和干扰 [3] - 公司预计将在2024年第三季度的业绩中计提18亿英镑的额外费用,用于州法院和Valisure的和解,以及剩余7%的州法院产品责任案件 [3] - 公司将通过现有资源为和解提供资金,并且没有改变研发投资计划的打算 [3]

GlaxoSmithKline (GSK, Financial) has agreed to a substantial settlement in connection with lawsuits related to its Zantac product in U.S. state courts. The company announced that it reached settlements with 10 plaintiff firms, which represent a significant 93% of the cases filed against the pharmaceutical company regarding Zantac. The total settlement amount is up to $2.2 billion. ...

GSK (GSK, Financial) announced that its respiratory syncytial virus (RSV) vaccine has shown protective benefits for three quarters following vaccination. The cumulative efficacy of the vaccine, adjusted for seasonal factors, stands at 62.9% for the elderly. This data is crucial for advisory panels, doctors, and patients when deciding which RSV vaccine to choose, as GSK faces strong competition from Pfizer (PFE) and Moderna (MRNA). The vaccine is approved for all adults aged 60 and above in the US and EU, as ...

Recent data indicates a significant drop in the sales of the respiratory syncytial virus (RSV) vaccine in the United States. Major vaccine manufacturers, including GlaxoSmithKline (GSK, Financial), Moderna, and Pfizer, face decreasing demand as independent pharmacists report a two-thirds decline in RSV vaccine uptake compared to the previous year. RSV poses a severe health risk to infants, older adults, and individuals with compromised immune systems, leading to numerous hospitalizations and deaths annually ...

GSK plc (GSK) announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in older adults (aged 50 years and older). The study achieved its primary endpoint of non-inferior immune response — study participants who received the co-administered shot generated immune responses that were similar to those generated in participants who received each vaccine separately. Study participants who received t ...

Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer September 16, 2024 8:00 AM EDT | Source: Kalm Therapeutics Inc. Huntsville, Alabama--(Newsfile Corp. - September 16, 2024) - Kalm Therapeutics (Kalm Tx) is pleased to announce the appointment of Dr. Tomoko Maeda-Chubachi, M.D., Ph.D., as our Chief Medical Officer. Dr. Maeda-Chubachi, a board-certified dermatologist will oversee the design and submission of our Phase 1b/2a clinical trial protocol to the FDA. "Altho ...

GSK plc (GSK) announced that its therapeutic herpes simplex virus (HSV) vaccine candidate, GSK3943104, did not meet the primary endpoint in the combined phase I/II proof-of-concept study. The phase I/II TH HSV REC-003 study evaluated the clinical efficacy of the early-stage HSV vaccine candidate GSK3943104. The company completed the primary objective data analysis from the phase II part of the phase I/II TH HSV REC-003 study, which demonstrated that GSK3943104 failed to meet the study's primary efficacy end ...

GSK's (GSK) phase III study evaluating its blockbuster drug Nucala (mepolizumab), an anti-IL5 biologic, for treating chronic obstructive pulmonary disease (COPD), met its primary endpoint. Data from the MATINEE study showed that in patients treated for up to 2 years, the addition of Nucala to inhaled maintenance therapy led to a statistically significant and clinically meaningful reduction in the annualized rate of moderate/severe exacerbations versus placebo, thereby meeting the study's primary endpoint. C ...

It has been about a month since the last earnings report for GSK (GSK) . Shares have added about 10.3% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Glaxo due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Beats Q2 Earnings & Sales Estimates, Ups 2024 Guidance GSK ...